Key Quantitative Figures - Standalone (INR Million)

Income Statement

  • Revenue from Operations: ₹726.60 (Q1 FY27) vs ₹634.90 (Q1 FY26) - 14% increase
  • Other Income: ₹16.83 (Q1 FY27) vs ₹9.46 (Q1 FY26)
  • Total Income: ₹743.43 (Q1 FY27) vs ₹644.36 (Q1 FY26)
  • Profit Before Tax: ₹197.52 (Q1 FY27) vs ₹102.88 (Q1 FY26) - 92% increase
  • Tax Expense: ₹50.41 (₹45.57 current tax + ₹4.84 deferred tax)
  • Profit After Tax: ₹147.11 (Q1 FY27) vs ₹78.38 (Q1 FY26) - 88% increase
  • Earnings Per Share (Face Value ₹10): ₹17.29 (Q1 FY27) vs ₹9.21 (Q1 FY26)

Expense Breakdown

  • Cost of material consumed: ₹107.92
  • Purchases of stock-in-trade: ₹55.16
  • Change in inventories: (₹3.48)
  • Employee benefits expense: ₹131.81
  • Finance cost: ₹13.64
  • Depreciation and amortization: ₹49.18
  • Other expenses: ₹191.68
  • Total Expenses: ₹545.91

Key Quantitative Figures - Consolidated (INR Million)

Income Statement

  • Revenue from Operations: ₹772.44 (Q1 FY27) vs ₹841.05 (Q1 FY26) - 8% decrease
  • Other Income: ₹16.43 (Q1 FY27) vs ₹23.16 (Q1 FY26)
  • Total Income: ₹788.87 (Q1 FY27) vs ₹864.21 (Q1 FY26)
  • Profit Before Tax: ₹1,016.82 (Q1 FY27) vs ₹201.87 (Q1 FY26) - 404% increase
  • Tax Expense: ₹49.50 (₹45.57 current tax + ₹3.93 deferred tax)
  • Profit After Tax: ₹967.32 (Q1 FY27) vs ₹172.96 (Q1 FY26) - 459% increase
  • Earnings Per Share (Face Value ₹10): ₹113.71 (Q1 FY27) vs ₹20.33 (Q1 FY26)
  • Exceptional Items: ₹853.49 million gain from loan restructuring

Subsidiary and Joint Venture Details

Consolidated results include:

  • Hester Biosciences Nepal Private Limited (Subsidiary)
  • Hester Biosciences Africa Limited (Subsidiary)
  • Hester Biosciences Kenya Limited (Subsidiary)
  • Hester Biosciences Tanzania Limited (Step-Down Subsidiary)
  • Thrishool Exim Limited (Joint Venture Entity)

Segment Performance - Standalone (INR Million)

Revenue by Segment

  • Poultry Healthcare: ₹618.16 (Q1 FY27) vs ₹416.68 (Q1 FY26)
  • Animal Healthcare: ₹108.44 (Q1 FY27) vs ₹218.22 (Q1 FY26)
  • Total Revenue: ₹726.60 (Q1 FY27) vs ₹634.90 (Q1 FY26)

Segment Results

  • Poultry Healthcare Profit: ₹245.19 (Q1 FY27) vs ₹89.69 (Q1 FY26)
  • Animal Healthcare Loss: (₹8.47) (Q1 FY27) vs ₹35.25 profit (Q1 FY26)
  • Total Segment Results: ₹236.72 (Q1 FY27) vs ₹124.94 (Q1 FY26)

Segment Performance - Consolidated (INR Million)

Revenue by Segment

  • Poultry Healthcare: ₹621.33 (Q1 FY27) vs ₹421.22 (Q1 FY26)
  • Animal Healthcare: ₹151.11 (Q1 FY27) vs ₹419.83 (Q1 FY26)
  • Total Revenue: ₹772.44 (Q1 FY27) vs ₹841.05 (Q1 FY26)

Segment Results

  • Poultry Healthcare Profit: ₹243.07 (Q1 FY27) vs ₹92.29 (Q1 FY26)
  • Animal Healthcare Loss: (₹41.85) (Q1 FY27) vs ₹132.11 profit (Q1 FY26)
  • Total Segment Results: ₹201.22 (Q1 FY27) vs ₹224.40 (Q1 FY26)

Exceptional Items

Standalone

During previous year (11 March 2026), Board approved divestment of 43.81% equity shareholding in subsidiary Texas Lifescience Private Limited (TLPL) by sale of 2,163,377 equity shares at ₹42.34 per share to existing promoter shareholders. TLPL ceased to be subsidiary from 27 March 2026.

Consolidated

During current quarter, Hester Biosciences Africa Limited entered into loan amendment agreement with Gates Foundation (USA), reducing outstanding principal from USD 12.00 million to USD 5.00 million, waiving all accrued interest, and making revised loan interest-free. This resulted in exceptional gain of ₹853.49 million recognized under Ind AS 109.

Board Meeting Details

  • Meeting held: 30 July 2026
  • Commenced: 10:30 a.m. (IST)
  • Concluded: 11:07 a.m. (IST)
  • Results approved by Board of Directors and reviewed by Audit Committee (meeting held 29 July 2026)

Press Release Highlights

Standalone Performance

  • Poultry Healthcare Division: ₹617.69 million, up 48% YoY
  • Animal Healthcare Division: ₹108.44 million, down 50% YoY
  • Gross Profit Margin: 78% vs 69% in Q1 FY26
  • EBITDA: ₹260.34 million, up 95% YoY
  • PAT Margin: 20% vs 12% in Q1 FY26

Consolidated Performance

  • Gross Profit Margin: 78% vs 73% in Q1 FY26
  • EBITDA: ₹1,118.06 million, up 327% YoY
  • PAT Margin: 125% vs 21% in Q1 FY26
  • Exceptional gain of ₹853.49 million from Gates Foundation loan restructuring

Management Commentary

  • Poultry growth driven by higher institutional business, deeper market penetration
  • Animal Healthcare impacted by timing of government-led immunization programs
  • Nepal operations experienced variability in institutional order timing
  • Africa business focused on strengthening registrations and market development
  • Company strategy: "Building with Intent. Growing with Science"

Forward-Looking Focus Areas for FY27

1. Strengthening biologicals portfolio across Poultry and Animal Healthcare

2. Expanding market penetration across domestic and export markets

3. Advancing Research and Development through new products and regulatory submissions

4. Improving manufacturing efficiency and enhancing utilization of recently commissioned facilities

5. Strengthening operational excellence, cost discipline and execution capabilities